why choose us

First received: December 5, 2022

Clinical Trial: FAPI PET for Response Evaluation and Prognosis Prediction in Liver and Biliary Cancer Patients Treated With PD-1 Combination Therapy

Study Status: Active, not recruiting

Recruit Status: Active, not recruiting

Condition: Hepatocellular Carcinoma
Bile Duct Cancer

Study Type: Observational


Official Title: 68Ga-FAPI PET for Response Evaluation and Prognosis Prediction in Advanced Liver and Biliary Cancer Patients Treated With PD-1 Based Combination Therapy: A Head-to-head Comparison to 18F-FDG PET

Brief Summary: The purpose of this study is to explore the ability of positron emission tomography (PET) with [68Ga]FAPI to detect, evaluate treatment response, and predict prognosis in advanced liver and biliary cancer patients treated with anti-PD-1 antibodies-based combination therapy.

Read more